

Article type : Letter to the Editor

What do monitoring platelet counts in COVID-19 teach us?

Jecko Thachil

Affiliations: 1 Department of Haematology, Manchester University Hospitals, Oxford road, Manchester, United Kingdom.

Author for correspondence: Dr Jecko Thachil, Department of Haematology, Manchester Royal Infirmary, Oxford road, Manchester, United Kingdom. M13 9WL.

Phone: 0044 161 276 6448

Fax: 0044 161 276 8085

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/JTH.14879](#)

This article is protected by copyright. All rights reserved

Email: jecko.thachil@mft.nhs.uk

Conflicts of interests: None

Yang and colleagues published the relevance of thrombocytopenia in COVID-19 patients and its association with mortality in this condition in the Journal of Thrombosis and Haemostasis.¹ The authors are to be applauded for the largest so-far analysis in the epidemiology of thrombocytopenia in patients with COVID-19. In addition to the association with mortality, there may be several other findings in this interesting paper which deserves mention. First of all, the study confirms that COVID-19 is not associated with significant thrombocytopenia (only 20.7% had counts less than $125 \times 10^9/L$, the lower range in this study).^{2,3} The 'higher' platelet counts for an illness as severe as COVID-19 is unusual and likely points towards liver activation and thrombopoietin release. After all, platelets can also be considered an acute phase reactant (like ferritin, fibrinogen, C-reactive protein which are all markedly raised in this disease) due to its antimicrobial repertoire which is increasingly recognised by the thrombosis and haemostasis community.^{4,5,6} The lung-specific entry of the SARS-CoV-2 suggests these platelets are one of the first lines of defence and gives proof to the concept of the presence of functional megakaryocytes in the lungs. In other words, the lung megakaryocytes (a previously disputed concept) in response to the liver thrombopoietin produce a large number of platelets locally to help in the host defence.⁷ In support of this, the authors do hypothesize SARS-CoV-2 could entrap megakaryocytes and blocks the release of

platelets as another reason for thrombocytopenia, which is interesting. But what would explain the poor prognosis from the lower platelet counts noted by Yang and colleagues?

Platelet counts less than $50 \times 10^9/L$ are extremely rare in COVID-19. According to the current study, the range of nadir platelet counts was $43 - 129 \times 10^9/L$. Although the authors suggest bone marrow involvement by the virus as another cause for the thrombocytopenia, the fact that rest of the blood counts are not always significantly affected in COVID-19, (haemoglobin and white cell counts apart from lymphopenia), points away from this mechanism. A more plausible reason is platelet being consumed to form pulmonary thrombi. Thrombus formation as an anti-infective process gained momentum in the last two decades.⁸ To serve this purpose, a bronchoalveolar haemostatic system exists to stop pathogen invasion into the bloodstream,⁹ but can be deleterious to the host, if it is widespread. Pulmonary micro-thrombi occur when the multiple efforts (including that of the platelets) to stop the infection have not succeeded and blocking the viral invasion has become necessary. In keeping with this hypothesis, Yang et al also show that those who had nadir platelet counts, the mortality decreased with the increasing of platelet count suggesting the thrombotic process has abated and platelets are no more consumed into the clot. The significance of this finding is that monitoring platelet counts in COVID-19 (and other infections and inflammatory states) is paramount since a decrease in the count after an initial surge may suggest the start of a process which may be harmful to the host (eg; micro-thrombi). For the same reason, improvement of the platelet counts may signify imminent clinical improvement. This approach would certainly benefit clinicians in low-resource settings where access to laboratory tests may be limited but a full blood count may be relatively easily performed.

Based on the 'platelet consumption' reason for thrombocytopenia and thus poor prognosis, in future studies, it would be useful to examine

- Whether anti-platelet agents are useful especially if anticoagulant drugs fail to stop the thrombotic process in COVID-19
- If inhalational antiplatelet drugs like heparin and prostacyclin analogues may be beneficial in worsening patients, similarly
- If patients already on antiplatelet agents for various cardiovascular disorders (and compliant with it) may be protected from severe COVID-19

- The timing of antiplatelet therapy – at a stage when they participate in microthrombi formation much more than the early phases when they may play a beneficial role (as described earlier)

Platelets continue to surprise us by being much more than the cellular component of the haemostatic system. And studies like that of Yang and colleagues help us to understand more about these multifaceted platelets, which do far more than just forming clots.

References

1. Yang X, Yang Q, Wang Y, et al . Thrombocytopenia and Its Association with Mortality in Patients with COVID-19. J Thromb Haemost epublished doi: 10.1111/JTH.14848
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513.
3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Feb 28. doi: 10.1056/NEJMoa2002032.
4. Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood. 2014 May 1;123(18):2759-67.
5. Herter JM, Rossaint J, Zarbock A. Platelets in inflammation and immunity. J Thromb Haemost. 2014 Nov;12(11):1764-75.
6. Manne BK, Xiang SC, Rondina MT. Platelet secretion in inflammatory and infectious diseases. Platelets. 2017 Mar;28(2):155-164
7. Lefrançois E, Ortiz-Muñoz G, Caudrillier A, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017 Apr 6;544(7648):105-109.

8. Posma JJ, Posthuma JJ, Spronk HM. Coagulation and non-coagulation effects of thrombin. *J Thromb Haemost.* 2016 Oct;14(10):1908-1916.

9. Glas GJ, Van Der Sluijs KF, Schultz MJ, Hofstra JJ, Van Der Poll T, Levi M. Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome. *J Thromb Haemost.* 2013 Jan;11(1):17-25.